Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
about
A framework for examining social stress and susceptibility to air pollution in respiratory healthAntenatal and postnatal corticosteroid and resuscitation induced lung injury in preterm sheep.Icariin ameliorates cigarette smoke induced inflammatory responses via suppression of NF-κB and modulation of GR in vivo and in vitroInterferon-inducible factor 16 is a novel modulator of glucocorticoid actionEvaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.Glucocorticoid dose determines osteocyte cell fate.Glucocorticoid efficacy in asthma: is improved tissue remodeling upstream of anti-inflammation.Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy.Glucocorticoids and osteocyte autophagy.Transcriptome remodeling in hypoxic inflammation.Salmeterol/fluticasone propionate combination in the treatment of COPD.A framework for examining social stress and susceptibility to air pollution in respiratory health.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?HDAC2 is required by the physiological concentration of glucocorticoid to inhibit inflammation in cardiac fibroblasts.
P2860
Q28390778-77242BFD-0E31-43B4-9460-B9527760CC76Q33574324-78E14C1A-ED82-4F18-B1E2-378D3952AA08Q33999187-7B371D71-9A7A-450E-B1CA-BEC3F179BFD0Q34395848-D835BD1B-EDC9-4667-84D8-CE9BCAA1B081Q34738020-888BB57D-4483-474F-B6E2-BE4E36AC641EQ35225093-F7D4778B-6E9A-4B8F-8698-654B028D5EEBQ35884698-C93AB1DD-2FC1-44FE-9F75-C5F6B0A52D02Q36822431-50D12A0A-366E-4BDF-9CD0-7A006BBB5C56Q37200430-4CBBBAD8-D437-4B18-81AE-4629CAAD5B53Q37720331-831EA205-244D-4611-8492-F24B8DE78A39Q37754942-AC9D200D-A6E1-4DFB-987A-E36772514AA6Q37778750-3510118A-838C-49D1-90A1-F3F5C99593FEQ37892531-499A5D7F-0E8F-4AE9-B854-BB65D20F92E8Q37951672-8BCBA3DF-4C70-4A40-8C01-FDD1986C16B2Q52868613-2A067519-88E6-4473-B1D2-D1D6529D93C7
P2860
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
@ast
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
@en
type
label
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
@ast
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
@en
prefLabel
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
@ast
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.
@en
P1476
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy
@en
P2093
Kazuhiro Ito
P304
313-9; discussion 340-1
P356
10.1513/PATS.200504-035SR
P577
2005-01-01T00:00:00Z